Skip to main
GRDN

GRDN Stock Forecast & Price Target

GRDN Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardian Pharmacy Service is well positioned in the long-term care market and has a promising growth potential as the industry consolidates. Additionally, the company has reliable sources of revenue from its pharmaceutical and medical products sales, along with a strong track record in acquisitions and a clean balance sheet. With a growing focus on optimizing operations, increasing MedicarePart D mix, and improving margins, Guardian Pharmacy Service has a positive outlook for future profitability, further supported by its strong financial flexibility and leading technology assets.

Bears say

Guardian Pharmacy Service is facing margin pressure due to its ongoing expansion activity and recent acquisitions. While the company's technology capabilities provide a competitive advantage, it remains to be seen if these expansions will result in meaningful earnings in the near future, as facilities typically take up to 4 years to reach full potential. However, the company's strong financial flexibility and robust pipeline of potential acquisitions suggest continued growth in the long-term.

GRDN has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardian Pharmacy Services Inc (GRDN) Forecast

Analysts have given GRDN a Strong Buy based on their latest research and market trends.

According to 5 analysts, GRDN has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardian Pharmacy Services Inc (GRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.